We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
1
Herrera-Estrella, M,
Apiquian, R,
Fresan, A,
Sanchez-Torres, I.
The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
BMC Psychiatry2005:5:22.
CrossRefGoogle ScholarPubMed
2
Atbasoglu, EC,
Ozguven, HD,
Can Saka, M,
Goker, C.
Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome.
J Clin Psychiatry2004;65:1724–1725.
CrossRefGoogle ScholarPubMed
3
Bottlender, R,
Jager, M,
Hofschuster, E,
Dobmeier, P,
Moller, HJ.
Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.
Pharmacopsychiatry2002;35:119–121.
CrossRefGoogle ScholarPubMed
4
American Psychiatry Association.
Diagnostic and statistical manual for mental disorders, 4th edn. Washington DC: American Psychiatry Association, 1994.
Google ScholarPubMed
5
Sachdev, P,
Mason, C,
Hadzi-Pavlovic, D.
Case-control study of neuroleptic malignant syndrome.
Am J Psychiatry1997;154:1156–1158.
Google ScholarPubMed